Table 1

Baseline characteristics of the study sample

LDL (in mg/dL) groupOverall sample (n=3012)Group 1
LDL <100
No treatment
(n=546)
Group 2
100≤ LDL <130
No treatment
(n=931)
Group 3
LDL <130
On treatment (n=170)
Group 4
LDL ≥130
No treatment (n=1233)
Group 5
LDL ≥130
On treatment (n=132)
Clinical and biochemical features
 Age, years; mean±SD58.4±9.656.2±9.757.9±9.763.7±8.558.4±9.362.7±7.6
 Women, n (%)1671 (55.5)348 (63.7)506 (54.4)75 (44.1)667 (54.1)75 (56.8)
 LDL cholesterol, mg/dL; mean±SD127.9±33.783.5±13.1115.7±8.4104.1±18.9156.9±23.1157.4±23.8
 Total cholesterol, mg/dL; mean±SD205.8±37.3163.0±22.6192.7±18.4182.2±26.1234.6±27.6238.2±30.6
 HDL cholesterol, mg/dL; mean±SD52.1±16.058.0±19.952.3±16.145.0±13.350.8±13.947.4±11.5
 Lipid-lowering treatment, n (%)302 (10.0)00170 (100.0)0132 (100.0)
 Statin treatment, n (%)224 (7.4)00140 (82.4)084 (63.6)
 Systolic BP, mm Hg; mean±SD127.7±18.6123.1±18.2126.6±18.3136.8±19.5128.8±18.3133.4±18.0
 Diastolic BP, mm Hg; mean±SD75.6±9.473.6±9.675.2±9.276.4±9.276.5±9.577.7±9.2
 Blood pressure-lowering treatment, n (%)726 (24.1)88 (16.1)227 (24.4)100 (58.8)256 (20.8)55 (41.7)
 Body mass index, kg/m²; mean±SD27.8±5.226.6±5.227.8±5.429.4±4.928.1±5.128.7±4.5
 Smoking, n (%)437 (14.5)75 (13.7)125 (13.4)14 (8.2)201 (16.3)22 (16.7)
 Diabetes, n (%)227 (7.5)37 (6.8)64 (6.9)37 (21.8)69 (5.6)20 (15.2)
 BNP, pg/mL, median (Q1, Q3)7.7 (4.0, 16.8)8.6 (4.0, 19.6)8.3 (4.0, 18.4)10.3 (4.0, 22.5)6.7 (4.0, 14.5)8.8 (4.0, 16.5)
 CRP, mg/L, median (Q1, Q3)2.0 (0.9, 4.5)1.8 (0.7, 5.0)1.8 (0.8, 3.9)2.4 (1.0, 5.0)2.1 (1.0, 4.5)2.8 (1.2, 4.8)
  • Sample size with available BNP levels, n=2997; sample size with available CRP levels, n=2909.

  • BNP, B-type natriuretic peptide; BP, blood pressure; CRP, C reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein.